You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Thermal Spray Dashboard/Knowledge Management System

    SBC: Engineering And Software System Solutions, Inc.            Topic: AF151166

    The USAF repair depots expend tremendous amounts of resources applying high technology thermal spray coatings to improve the performance of components and systems. In general, thermal spray application processes are complex, require high cost equipment th

    SBIR Phase II 2017 Department of DefenseAir Force
  2. Production Technology for Recombinant Intravenous Immunoglobulin

    SBC: Gigagen, Inc.            Topic: NIAID

    PROJECT SUMMARY Project TitleProduction Technology for Recombinant Intravenous Immunoglobulin OrganizationGigaGen IncPIDavid SJohnsonPh DIntravenous immunoglobulinor IVIgis a pool of antibodies isolated from the plasma of thousands of donorsIVIg therapy is used for several indicationsincluding B cell chronic lymphocytic leukemiaCLLautoimmune neuropathyand primary immunodeficiencyPIDIVIg sales are ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Improved Diagnosis of Kaposi's Sarcoma-Associated Herpesvirus Infection

    SBC: EPIPHANY BIOSCIENCES, INC.            Topic: R

    Project Summary Abstract Kaposiandapos s sarcoma herpes virusKSHVis an oncovirus that causes several cancers including Kaposiandapos s sarcomaKSIt is estimated thattoof U Sblood donors have been infected with KSHVyet in some high risk populations such as homosexual menprevalence is as high asIn spite of HAARTKS remains the second most common AIDSassociated malignancyA third of AIDS KS cases now ar ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. MR191_An Immunoprotectantfor Marburg Virus

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: NIAID

    PROJECT SUMMARY Mapp BiopharmaceuticalIncMappis developing antibody based therapeutics to treat a number of infectious agentsincluding some of the most dangerous known to manthe filovirusesMarburg virus is a filovirus endemic to Africa and causes an often lethal hemorrhagic feverPresently there are no approved vaccines or therapeutics to treat Marburg virus infections and this remains a major unme ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Therapeutic Antibodies for Biofilm Infections

    SBC: Trellis Bioscience, LLC            Topic: NIAID

    Abstract The CDC estimates thatof clinically significant drug resistant bacterial infections are drug refractory due to a change in physiological state of pathogens associated with biofilm formationTRLis a high affinitypMnative human monoclonal antibodymAbthat disrupts biofilms by extracting a key bacterial scaffolding proteinThe epitope is highly conserved in the target protein homologs across a ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Therapeutic Antibody for CMV

    SBC: Trellis Bioscience, LLC            Topic: NIAID

    Abstract Human cytomegalovirusHCMVis the major viral cause of medical complications associated with bone marrow and organ transplantationViral transmission from mother to fetus is implicated inof stillbirths andbirth defects annually in the USPassive immunization using human immune globulinHIGhas shown promising activity for both indicationsHIG is a complexvariable product that may cause side effe ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Advancing a novel potent Zika virus specific nucleoside analog to the clinic

    SBC: Riboscience LLC            Topic: R

    Our goal is to leverage our excitingSBIR Phaseequivalentresearch results into a novel nucleoside based treatment for Zika virusZIKVthat can be used for prevention or treatment of ZIKV infectionOur lead moleculeRBSis the first potent and specific inhibitor of ZIKV replicationECmicromolarCCandgtmicromolarand that is suitable for the development of both oral and intravenous dosage formsRBSis a prodru ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids

    SBC: ELYSIUM THERAPEUTICS, INC            Topic: NIDA

    Project SummaryAbstractAddiction is a diseaseAccording to the National Institute on Drug Abuseaddiction can be hereditaryand canbetriggeredbyenvironmentalconditionsandbehaviorOnekeyenvironmentalfactorinvolvesthereadyaccess to unused prescription opioids by potential abusersespecially teensElysium has discovered a novel molecular deactivationXpiRxorexpiring pilltechnology that is designedto effecti ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel Device for Optimal and Personalized Fluid Therapy in Septic Shock Patients

    SBC: Potrero Medical, Inc.            Topic: 300

    Abstract Septic shock is a severe condition resulting in a critical reduction of organ perfusion with consequential and common stageandacute kidney injuryAKIoccurring in as many asof patients and with an alarmingly high in hospital co morbid mortality rate of up toCurrent Surviving Sepsis Guidelines recommend early aggressive fluid resuscitation targeting mean arterial pressureMAPmmHghowever aggre ...

    SBIR Phase II 2017 Department of Health and Human Services
  10. Kinetic Phenotype Discovery Informatics for Neurological Diseases

    SBC: DRVISION TECHNOLOGIES LLC            Topic: 101

    Project Summary Neurological disorders significantly outnumber diseases in other therapeutic areas and are growing in incidence faster than any other disease classesHoweverthe pharmaceutical industry has been unsuccessful in coming up with effective drugsA big factor in these failures has been a lack of adequate model systems for fundamental disease understanding affecting both diagnosis and treat ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government